METTL3 inhibitor STM2457 impairs tumor progression and enhances sensitivity to anlotinib in OSCC.
Liu L, Zhao T, Zheng S, Tang D, Han H, Yang C, Zheng X, Wang J, Ma J, Wei W, Wang Z, He S, He Q.
Liu L, et al. Among authors: wang j, wang z.
Oral Dis. 2024 Feb 20. doi: 10.1111/odi.14864. Online ahead of print.
Oral Dis. 2024.
PMID: 38376115